University of Pennsylvania

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1740-11-14

Employees: 5K

Market Cap: -

Website: http://www.upenn.edu

Clinical Trials

Communicating Smoking Risks Through Graphic Warning Labels

Phase 3

Completed

Conditions: Lung Cancer
Heart Disease

Interventions: Behavioral: Control
Behavioral: Picture warning

First Posted Date: 2013-02-01

Last Posted Date: 2014-12-02

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 245

Registration Number: NCT01782053

Locations: 🇺🇸
Annenberg Public Policy Center, Philadelphia, Pennsylvania, United States
🇺🇸
Lazenby Hall, Ohio State University, Columbus, Ohio, United States

Remote Observed Dosing to Increase Suboxone Compliance

Not Applicable

Completed

Conditions: Opiate Dependence

Interventions: Behavioral: Remote Observed Dosing

First Posted Date: 2013-01-30

Last Posted Date: 2017-11-07

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 9

Registration Number: NCT01779973

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Intraoperative Imagery of Renal Nodules With Folate-fluorescein Conjugate(EC17)

Early Phase 1

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: EC17

First Posted Date: 2013-01-29

Last Posted Date: 2018-07-03

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 10

Registration Number: NCT01778933

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Pilot and Feasibility Study of the Imaging Potential of EC17: Intraoperative Folate-fluorescein Conjugate (EC17) Lung Cancer (CA)

Phase 1

Completed

Conditions: Nodules
Lung and Pleural Malignancies
Neoplasms
Adenocarcinoma

Interventions: Drug: EC17 imaging contrast agent

First Posted Date: 2013-01-29

Last Posted Date: 2016-05-17

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 48

Registration Number: NCT01778920

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Philadelphia VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States

Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers

Phase 2

Terminated

Conditions: HIV
Heavy Drinking
Alcohol Dependence

Interventions: Drug: Topiramate
Drug: Placebo
Behavioral: Medical Management

First Posted Date: 2013-01-09

Last Posted Date: 2016-03-15

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 4

Registration Number: NCT01764685

Locations: 🇺🇸
University of Pennsylvania Treatment Research Center, Philadelphia, Pennsylvania, United States

Extended Varenicline Treatment for Smoking Among Cancer Patients

Phase 3

Completed

Conditions: Nicotine Dependence

Interventions: Drug: Varenicline
Drug: Placebo
Behavioral: Smoking Cessation Counseling

First Posted Date: 2012-12-28

Last Posted Date: 2019-07-30

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 207

Registration Number: NCT01756885

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Test of Different Degrees of Cost Sharing on Program Uptake and Attendance

Not Applicable

Completed

Conditions: Obesity

Interventions: Behavioral: Different levels of cost sharing

First Posted Date: 2012-12-24

Last Posted Date: 2015-12-21

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 1239

Registration Number: NCT01756066

Locations: 🇺🇸
Ingersoll Rand, Davidson, North Carolina, United States
🇺🇸
Vanguard Health Systems, Nashville, Tennessee, United States

GlowCaps Adherence Randomized Control Trial

Completed

Conditions: Medical Adherence

Interventions: Device: GlowCap
Behavioral: Paid for adherence
Behavioral: Daily email, text message, or phone call reminders

First Posted Date: 2012-12-24

Last Posted Date: 2017-05-09

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 119

Registration Number: NCT01756001

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Effects of ABT-089 on Smoking Abstinence Symptoms and Reward

Phase 2

Terminated

Conditions: Nicotine Addiction

Interventions: Drug: Placebo
Drug: ABT-089

First Posted Date: 2012-12-24

Last Posted Date: 2014-10-29

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 17

Registration Number: NCT01756053

Locations: 🇺🇸
Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Dose Optimization Trial of CD19 Redirected Autologous T Cells

Phase 2

Completed

Conditions: Adult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL

Interventions: Biological: CART-19

First Posted Date: 2012-12-11

Last Posted Date: 2023-06-22

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 42

Registration Number: NCT01747486

Locations: 🇺🇸
Abramsonc Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy